Cargando…

New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine

Anti-SARS-CoV-2 vaccines are safe and effective, also in individuals with allergic and immune-mediated diseases (IMDs). There are reports suggesting that vaccines may be able to trigger de-novo or exacerbate pre-existing IMDs in predisposed individuals. Eosinophilic granulomatosis with polyangiitis...

Descripción completa

Detalles Bibliográficos
Autores principales: Nappi, Emanuele, De Santis, Maria, Paoletti, Giovanni, Pelaia, Corrado, Terenghi, Fabrizia, Pini, Daniela, Ciccarelli, Michele, Selmi, Carlo Francesco, Puggioni, Francesca, Canonica, Giorgio Walter, Heffler, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144767/
https://www.ncbi.nlm.nih.gov/pubmed/35632472
http://dx.doi.org/10.3390/vaccines10050716
_version_ 1784716128529940480
author Nappi, Emanuele
De Santis, Maria
Paoletti, Giovanni
Pelaia, Corrado
Terenghi, Fabrizia
Pini, Daniela
Ciccarelli, Michele
Selmi, Carlo Francesco
Puggioni, Francesca
Canonica, Giorgio Walter
Heffler, Enrico
author_facet Nappi, Emanuele
De Santis, Maria
Paoletti, Giovanni
Pelaia, Corrado
Terenghi, Fabrizia
Pini, Daniela
Ciccarelli, Michele
Selmi, Carlo Francesco
Puggioni, Francesca
Canonica, Giorgio Walter
Heffler, Enrico
author_sort Nappi, Emanuele
collection PubMed
description Anti-SARS-CoV-2 vaccines are safe and effective, also in individuals with allergic and immune-mediated diseases (IMDs). There are reports suggesting that vaccines may be able to trigger de-novo or exacerbate pre-existing IMDs in predisposed individuals. Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, eosinophilia, and eosinophil-rich granulomatous inflammation in various tissues. We describe the case of a 63-year-old man who experienced cardiac, pulmonary, and neurological involvement one day after the administration of the booster dose of anti-SARS-CoV-2 vaccine (mRNA-1273). A diagnosis of EGPA was made and the patient was treated with high-dose steroids and cyclophosphamide, with a good clinical response. Interestingly, our patient had experienced a significant worsening of his pre-existing asthma six months earlier, just after the first two vaccine shots with the ChAdOx1 anti-SARS-CoV-2 vaccine. It is impossible to know whether our patient would have had developed EGPA following natural SARS-CoV-2 infection or at some point in his life regardless of infectious stimuli. Nevertheless, our report may suggest that caution should be paid during the administration of additional vaccine doses in individuals who experienced an increase in IMD severity that persisted over time following previous vaccine shots.
format Online
Article
Text
id pubmed-9144767
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91447672022-05-29 New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine Nappi, Emanuele De Santis, Maria Paoletti, Giovanni Pelaia, Corrado Terenghi, Fabrizia Pini, Daniela Ciccarelli, Michele Selmi, Carlo Francesco Puggioni, Francesca Canonica, Giorgio Walter Heffler, Enrico Vaccines (Basel) Case Report Anti-SARS-CoV-2 vaccines are safe and effective, also in individuals with allergic and immune-mediated diseases (IMDs). There are reports suggesting that vaccines may be able to trigger de-novo or exacerbate pre-existing IMDs in predisposed individuals. Eosinophilic granulomatosis with polyangiitis (EGPA) is a small-vessel vasculitis characterized by asthma, eosinophilia, and eosinophil-rich granulomatous inflammation in various tissues. We describe the case of a 63-year-old man who experienced cardiac, pulmonary, and neurological involvement one day after the administration of the booster dose of anti-SARS-CoV-2 vaccine (mRNA-1273). A diagnosis of EGPA was made and the patient was treated with high-dose steroids and cyclophosphamide, with a good clinical response. Interestingly, our patient had experienced a significant worsening of his pre-existing asthma six months earlier, just after the first two vaccine shots with the ChAdOx1 anti-SARS-CoV-2 vaccine. It is impossible to know whether our patient would have had developed EGPA following natural SARS-CoV-2 infection or at some point in his life regardless of infectious stimuli. Nevertheless, our report may suggest that caution should be paid during the administration of additional vaccine doses in individuals who experienced an increase in IMD severity that persisted over time following previous vaccine shots. MDPI 2022-05-03 /pmc/articles/PMC9144767/ /pubmed/35632472 http://dx.doi.org/10.3390/vaccines10050716 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Nappi, Emanuele
De Santis, Maria
Paoletti, Giovanni
Pelaia, Corrado
Terenghi, Fabrizia
Pini, Daniela
Ciccarelli, Michele
Selmi, Carlo Francesco
Puggioni, Francesca
Canonica, Giorgio Walter
Heffler, Enrico
New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
title New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
title_full New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
title_fullStr New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
title_full_unstemmed New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
title_short New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine
title_sort new onset of eosinophilic granulomatosis with polyangiitis following mrna-based covid-19 vaccine
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9144767/
https://www.ncbi.nlm.nih.gov/pubmed/35632472
http://dx.doi.org/10.3390/vaccines10050716
work_keys_str_mv AT nappiemanuele newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine
AT desantismaria newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine
AT paolettigiovanni newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine
AT pelaiacorrado newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine
AT terenghifabrizia newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine
AT pinidaniela newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine
AT ciccarellimichele newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine
AT selmicarlofrancesco newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine
AT puggionifrancesca newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine
AT canonicagiorgiowalter newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine
AT hefflerenrico newonsetofeosinophilicgranulomatosiswithpolyangiitisfollowingmrnabasedcovid19vaccine